CD40 antibodies for the treatment of human malignancy
CD40 is an important antigen involved in immune regulation and anti-CD40 antibody
therapies against human CD40 expressing tumours may be particularly advantageous.
The antibody could induce tumour response in two ways. Firstly it might have a direct
anti-tumour effect and secondly it could 'boost' the immune system to provide a
heightened immune response that evades tumour tolerance.
This project has explored the effects of CD40 ligation of a variety of CD40 expressing
tumours including transformed human B cell lines (RL and Daudi), human epithelial cell
lines (MG79 [ovarian] and Caski [cervical]) and primary human B cell non-Hodgkin's
lymphomas obtained, with consent, from patients undergoing excision lymph node
biopsy or splenectomy.
The ligation of CD40, on transformed human B cell lines, using chinese hamster ovary
cells transfected to express human CD40L and human soluble CD40L has shown
significant cellular growth inhibition (p